Veri announces seed round of 4 million USD for further development of its solution to tackle metabolism issues

Earlier this month, Finnish healthtech Veri announced the successful closing of its 4 million USD seeding round. The round was led by PROFounders, and closely followed by Lifeline Ventures, Accel with angel investors like Johannes Schildt (CEO and co-founder of Kry/Livi) and Kristian Ranta (CEO and co-founder of Meru Health). While the round also includes the company’s previous pre-seed investment by Lifeline Ventures. 

Veri was launched following with a personal need for optimised solutions relating to metabolistic issues. The team wanted to  build something that would promote prevention, transparency and collaboration to the medical and the health community. The idea of empowering people to take charge of their own health grew extremely strong within the company and this is exactly what their product has to offer.

The combination of the Veri’s app and the wearable glucose sensor, is able to give people an approach to help everyone make better food choices in an effortless and deeply personalized way.

Throughout the last year, Veri has focused on developing the product which is already being used by over 1,500 people. While during the same period, the team has grown from just 4 people to 15 and plans to keep pushing in terms of both product development and team expansion.

In 2021, Veri is planning to unveil major new features, an Android app and other improvements, such as the new UI update and building a data-driven recommendation engine. While the newly secured funding will allow further developing of the solution, scaling of the team and reaching a broader audience while it has already scheduled shipping to US-based customers this week.

Making Veri one step close to making blood sugar the next heart rate.